DDX49 is a novel biomarker and therapeutic target for lung cancer metastases
DDX49 is a novel biomarker and therapeutic target for lung cancer metastases
复制标题
DDX49是肺癌转移的新型生物标志物和治疗靶点
DOI：
10.1111/jcmm.14734
复制
发表时间：
2019-11-20
影响因子：
5.3
通讯作者：
Zhang, Zhimin
中科院分区：
文献类型：
--
作者：
Lian, Xiaojuan;Xiang, Debing;Zhang, Zhimin
淋巴结转移的识别对肺癌的诊断、治疗和预后具有重要意义。我们发现DDX 49通过Akt/beta-catenin途径与肺癌淋巴结转移相关。使用转录组测序、生物信息学分析、定量RT-PCR、细胞转染和癌症基因组图谱（TCGA）数据集来鉴定负责淋巴结转移的DDX 49。利用京都基因和基因组百科全书（KEGG）途径富集分析在实验细胞中探索可能的分子机制。DDX 49基因与肺癌淋巴结转移显著相关。DDX 49基因的敲低可抑制PC-9和H460细胞的增殖和迁移。机制研究发现，DDX 49的表达下调可使肺癌细胞Akt/beta-catenin信号通路减弱。体内实验表明DDX 49通过增加Akt/beta-catenin通路促进肺癌细胞增殖和转移。这些结果表明，DDX 49可能是一种新的生物标志物的淋巴结转移和肺癌转移的治疗靶点。
The identification of lymph node metastases is important for the diagnosis, treatment and prognosis of patients with lung cancer. We found DDX49 was associated with the lymph node metastases in lung cancer by the Akt/beta-catenin pathway. Transcriptome sequencing, bioinformatics analysis, quantitative RT-PCR, cell transfection and the Cancer Genome Atlas (TCGA) data set were used to identify DDX49 responsible for lymph node metastases. A Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to explore the possible molecular mechanism in experimental cell. The DDX49 gene was correlated significantly with lymph node metastases of lung cancer. The knockdown of DDX49 inhibited the cell proliferation and migration in PC-9 and H460 cells. The mechanism research found downexpression of DDX49 decreased the Akt/beta-catenin pathway in lung cancer cell. In vivo experiments showed that DDX49 promoted the proliferation and metastases of lung cancer cells by increasing the Akt/beta-catenin pathway. These findings suggested that DDX49 may be useful as a novel biomarker of lymph node metastases and therapeutic target for lung cancer metastasis.